A5056305013- Hepatitis C virus research
- Liver Disease Diagnosis and Treatment
- Hepatitis B Virus Studies
- Ultra-Wideband Communications Technology
- Wireless Communication Networks Research
- Antenna Design and Analysis
- HIV/AIDS drug development and treatment
- Microwave Imaging and Scattering Analysis
- Advanced Wireless Communication Techniques
- Liver physiology and pathology
- Chronic Lymphocytic Leukemia Research
- Oral and Maxillofacial Pathology
- Cancer, Hypoxia, and Metabolism
- Breast Cancer Treatment Studies
- Immune Cell Function and Interaction
- Hepatitis Viruses Studies and Epidemiology
- Industrial Technology and Control Systems
- Engineering Applied Research
- Gyrotron and Vacuum Electronics Research
- Virus-based gene therapy research
- Advanced Wireless Network Optimization
- Cancer and Skin Lesions
- Neuroendocrine Tumor Research Advances
- interferon and immune responses
- Breast Lesions and Carcinomas
The University of Tokyo
2023-2024
Osaka Dental University
2017-2024
Tokyo University of Science
2005-2024
Unicharm (Japan)
2017-2024
Hiroshima University Hospital
2024
Nippon Koei (Japan)
2016-2023
Graco (United States)
2022-2023
Shiga Medical Center
2021
Toranomon Hospital
2020
Nagaoka University of Technology
2020
All-oral combinations of direct-acting antivirals may improve efficacy and safety outcomes for patients with hepatitis C virus (HCV) infection, particularly those who are poor candidates current interferon/ribavirin-based regimens. In this open-label, phase 3 study, 135 interferon-ineligible/intolerant 87 nonresponder chronic HCV genotype 1b infection were enrolled at 24 centers in Japan. Patients received daclatasvir 60 mg once daily plus asunaprevir 100 twice weeks. The primary endpoint...
Patients with chronic hepatitis C virus (HCV) infection and previous null response to pegylated interferon (Peg-IFN) ribavirin (RBV) have limited therapeutic options. HCV genotype 1 is the most common worldwide difficult treat; 1b subtype of outside North America. The enhanced antiviral activity achieved by combining two direct-acting (DAA) agents may improve clinical outcomes. This open-label, phase IIa study included 10 patients (<2 log10 reduction in RNA after 12 weeks) Peg-IFN RBV....
Abstract BACKGROUND Hepatic steatosis is one of the histopathologic features chronic hepatitis C. It was reported recently that expression C virus (HCV) core protein in transgenic mice induced hepatocellular carcinoma (HCC) association with steatosis. The objective this study to determine relation between hepatic and hepatocarcinogenesis patients HCV infection. METHODS authors studied 161 infection who were diagnosed at Nagasaki University Hospital, Nagasaki, Japan, January 1980 December...
RNA interference (RNAi) is the process by which double-stranded directs sequence-specific degradation of mRNA. In mammalian cells, RNAi can be triggered 21-nucleotide duplexes short interfering (siRNA). We examined effects siRNA on hepatitis B virus (HBV) replication. Human hepatoma cells were transfected with HBV DNA and against HBV-pregenome RNA. Transfection experiments demonstrated that reduced amount resulted in reduction levels replicative intermediates viral protein. Our results...
Angiogenesis is a key determinant and rate-limiting step in tumor progression metastatic spread. As pituitary tumor-transforming gene (PTTG) induces basic fibroblast growth factor (bFGF), we tested angiogenesis induced by conditioned medium (CM) derived from NIH-3T3 transfectants overexpressing wild-type human PTTG (WT-hPTTG-CM). We also examined the relationship between expression vascularity series of tumors. CM Wt-hPTTG proliferation, migration, tube formation umbilical vein endothelial...
Oral daclatasvir (DCV; pangenotypic NS5A inhibitor) plus asunaprevir (ASV; NS3 protease is approved in Japan and Korea for treatment of chronic hepatitis C virus (HCV) genotype 1. Response to DCV + ASV affected by resistance-associated polymorphisms (RAPs) HCV NS5A. The prevalence influence these RAPs on 12-week sustained virologic response (SVR12) was evaluated Asian non-Asian patients. Data were pooled from 5 national international studies patients with 1b (GT-1b) receiving at their...
Background: Factors associated with response to lenvatinib have not been clarified in patients hepatocellular carcinoma (HCC). Patients and Methods: This study retrospectively analyzed 50 treated as first-line therapy between March 2018 2019. were divided into two groups by the Modified Response Evaluation Criteria Solid Tumours (mRECIST) (responders non-responders, whose best overall responses complete (CR)/partial (PR) stable (SD)/progressive disease (PD), respectively). assessed,...
Nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit cyclooxygenase (COX) activity and are considered to exert antitumor actions in a variety of cancer cells, although the effects unlikely entirely due COX inhibition. Because clinical observations suggest that hepatocyte growth factor (HGF) can promote metastasis hepatoma cells while stimulating tumor invasiveness, we investigated effect aspirin NS-398, selective COX-2 inhibitor, on HGF-mediated invasiveness HepG2 human cells. HGF...
Pigment epithelium-derived factor (PEDF) is one of the most powerful endogenous antiangiogenic reagents discovered to date. Its potential in neoplastic disease remains unclear. In this study, we investigated property PEDF hepatocellular carcinoma (HCC), a typical hypervascular tumor. HCC cell lines, constitutive messenger RNA and protein expression varied. Genomic DNA encoding gene was same lines examined by Southern blotting. chemically induced hypoxic conditions, secreted suppressed...
Abstract Background and Aims: Hepatitis B virus (HBV) is considered a major risk factor for the progression to liver cirrhosis hepatocellular carcinoma (HCC). The serum level of HBV‐DNA correlated with disease. aim present study was determine relationship between hepatocarcinogenesis in patients chronic HBV infection. Methods: authors studied 73 who were diagnosed infection at Nagasaki University Hospital (Nagasaki, Japan) January 1980 December 1999. significance age, sex, habitual drinking,...
Daclatasvir combined with asunaprevir is the first all-oral, ribavirin-free treatment of hepatitis C virus genotype 1b infection in Japan. This study compared efficacy and safety daclatasvir plus versus telaprevir peginterferon/ribavirin Japanese treatment-naive patients infected 1b.Treatment-naive (20-70 years; baseline viral load, ≥ 100,000 IU/mL) were randomly assigned (stratified by IL28B rs8099917 TT/non-TT status) to receive either 60 mg tablets once daily 100 softgel capsules twice...
This study aimed to determine the safety and efficacy of atezolizumab + bevacizumab therapy in hepatocellular carcinoma patients receiving anti-platelet agents or anticoagulants.
A 3.1-to-9.5GHz UWB transceiver is implemented in 90nm CMOS technology. It includes a 12-band synthesizer and wideband TX/RX chains operating from 1.1V supply. The provides TX0IP3 of 7.2 to 8.6dBm, an RX gain 58 64dB, NF 6.3 7.8dB across 12 bands
Background Daclatasvir (DCV; BMS-790052) is a picomolar inhibitor of HCV non-structural protein 5A (NS5A) and has demonstrated efficacy in patients chronically infected with HCV. Methods In the double-blind, randomized studies AI444021 AI444022, 71 Japanese genotype 1 (predominantly 1b) received DCV (10 mg or 60 mg) plus peginterferon alfa-2b alfa-2a ribavirin. Virological failure occurred 14% (5/36) treatment-naive 54% (19/35) prior alfa/ribavirin non-responders. Resistance testing was...